Voyager Therapeutics (NASDAQ:VYGR) Posts Earnings Results, Beats Estimates By $0.01 EPS

Voyager Therapeutics (NASDAQ:VYGR) announced its earnings results on Thursday. The company reported ($0.40) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.41) by $0.01, FiscalAI reports. The company had revenue of $0.61 million for the quarter, compared to analyst estimates of $6.35 million. Voyager Therapeutics had a negative return on equity of 57.92% and a negative net margin of 312.63%.

Voyager Therapeutics Stock Performance

Shares of NASDAQ VYGR traded down $0.15 during midday trading on Thursday, reaching $1.72. The company’s stock had a trading volume of 1,302,634 shares, compared to its average volume of 666,221. The company has a market cap of $105.98 million, a P/E ratio of -0.96 and a beta of 1.20. The business’s 50 day moving average price is $2.61 and its two-hundred day moving average price is $3.43. Voyager Therapeutics has a fifty-two week low of $1.68 and a fifty-two week high of $5.48.

Analyst Ratings Changes

Several research analysts have weighed in on the company. HC Wainwright reiterated a “buy” rating on shares of Voyager Therapeutics in a research report on Thursday, August 27th. Weiss Ratings reissued a “sell (d-)” rating on shares of Voyager Therapeutics in a research report on Friday, October 9th. One research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Voyager Therapeutics currently has a consensus rating of “Moderate Buy” and an average price target of $16.50.

About Voyager Therapeutics

Voyager Therapeutics, Inc is a biotechnology company focused on developing gene therapies for neurological diseases. The company aims to address conditions affecting the central nervous system by using adeno-associated virus (AAV) gene-delivery technologies to deliver therapeutic genes to targeted areas of the brain and nervous system.

Voyager’s research platform, known as TRACER, is designed to identify AAV capsids with improved ability to cross the blood-brain barrier and reach the central nervous system.